Recommended Topic Related To:

Raxar

"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...

Raxar

Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

DRUG DESCRIPTION

RAXAR Tablets contain grepafloxacin hydrochloride RAXAR (grepafloxacin) is a broad-spectrum fluoroquinolone antimicrobial agent for oral administration.

The chemical name for grepafloxacin is (±)-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl- 7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid monohydrochloride sesquihydrate. Its molecular formula is C19H22FN3O3HCl 3/2 H2O and it has a molecular weight of 422.88. It is soluble in water and very slightly soluble in ethanol.

RAXAR (grepafloxacin) Tablets are white to pale yellow, film-coated, biconvex, bevel-edged tablets containing either 200 mg, 400 mg, or 600 mg of grepafloxacin base, formulated as a hydrochloride salt. Each tablet contains the following inactive ingredients: low substituted hydroxypropyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose 2910, magnesium stearate, microcrystalline cellulose, talc, and titanium dioxide.

Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.